SHERLOC: New Deep Learning Model Improves Cancer Prognosis Using Blood-Based Tumor DNA Monitoring
Researchers developed SHERLOC, a deep learning framework that analyzes circulating tumor DNA (ctDNA) from blood samples to predict survival outcomes in cancer patients undergoing treatment. The model combines temporal analysis of genetic variants with pre-trained cancer genomics data within a traditional survival analysis framework. The approach outperformed existing methods in lung cancer trials and could help doctors make earlier treatment decisions based on blood tests rather than waiting for imaging results.
SHERLOC is a new artificial intelligence model designed to analyze longitudinal blood-based measurements of circulating tumor DNA to predict patient survival and treatment response in cancer. The framework addresses key challenges in clinical trials, including the high complexity of genetic data and small sample sizes, by integrating multiple analytical approaches: tracking changes in gene variants over time, monitoring panel-level biomarkers, and leveraging pre-trained knowledge from large cancer datasets. When tested on lung cancer patients from the phase III IMpower150 trial, SHERLOC demonstrated superior performance compared to statistical, ensemble, and other deep learning methods in predicting survival and calibrating risk estimates. Importantly, the model remained interpretable—meaning clinicians can understand why it makes specific predictions—and performed well even when fewer blood samples were available per patient. The ctDNA-based risk scores provided prognostic information independent of and complementary to standard imaging assessments, potentially enabling earlier treatment adjustments and better patient stratification.
What's missing
The article does not discuss potential limitations such as the need for validation in independent patient cohorts, cost-effectiveness compared to standard imaging, or the timeline for potential clinical implementation. It also lacks discussion of how this approach compares to other emerging liquid biopsy technologies or whether results generalize to cancer types beyond lung cancer.
How coverage differed
This is a preprint from bioRxiv presenting original research with neutral scientific framing. The source presents methodology and results objectively without sensationalism, though as a research announcement it naturally emphasizes the model's advantages and potential clinical applications.
What different sources said
- bioRxivCenter
SHERLOC: An interpretable deep learning model for longitudinal circulating tumor DNA data in survival analysis
Related
Widespread US Heat Wave Brings Dangerous Temperatures Across Multiple Regions
A significant heat wave is spreading across the central United States with heat index values forecast to exceed 110 degrees in parts of Texas and 100 degrees across multiple states including Missouri, Kansas, Iowa, Arkansas, and Tennessee. The National Weather Service warns that early-season heat waves pose greater risks for heat-related illness and could break daily temperature records across numerous states. The extreme heat is expected to impact more than 20 cities, with temperatures 10-20 degrees above normal in some regions, particularly the Upper Midwest and Great Lakes area.
Study Finds Noncognitive Skills Like Motivation and Curiosity Critical to Academic Success
Researchers at Queen Mary University of London conducted a major study showing that noncognitive skills such as motivation, curiosity, academic interest, and self-belief significantly influence how children translate their genetic potential into actual academic achievement. The research highlights that beyond innate ability, psychological and behavioral factors are essential determinants of educational outcomes. This finding suggests that interventions targeting motivation and attitude may be as important as traditional academic support in improving student performance.
NASA Announces Four-Person Crew for Artemis III Moon Mission
NASA has announced the crew for Artemis III, consisting of NASA astronauts Andre Douglas, Randy Bresnik, and Frank Rubio, along with ESA astronaut Luca Parmitano. The mission will test integrated operations between NASA's Orion spacecraft and commercial lunar landers from SpaceX and Blue Origin. This represents a significant step in NASA's plan to return humans to the Moon and establish sustainable lunar exploration capabilities.